Is an ApoB of 95 high?

Most laboratories would flag it as above desirable (under 90). It sits above the European moderate-risk goal of 100 only if other risk is present, and above the high-risk goal of 80. Whether it matters depends on the rest of the picture: age, blood pressure, family history, lipoprotein(a), and how long it has been there.

What ApoB level is optimal?

No study has found a floor below which lower stops helping. Guidelines set goals under 100, 80 or 65 mg/dL depending on risk, and the lower-risk half of a healthy US population sits below about 80. 'Optimal' is therefore a statement about risk tolerance and years of exposure, not a single number.

My LDL is fine. Do I need ApoB?

Possibly. At an LDL of 100 the ApoB in a US population ranged from 66 to 99, and people with high ApoB and normal LDL carried higher risk than those with both low. ApoB is a single, standardized, non-fasting test that settles the question.

Longevity Library · Lab reference

Written by Daniel Tagge, MD
Updated October 7, 2026
Reviewed October 10, 2026
19 sources · Measured in mg/dL

System: Metabolism & Metabolomics

ApoBApolipoprotein B · ApoB-100

Name: ApoB: normal range, what the evidence supports, and what moves it
Creator: Daniel Tagge, MD
Published: 2026-10-07

Cardiovascular risk falls continuously as ApoB falls and no floor has been found. Guidelines set treatment goals below 100, 80 or 65 mg/dL depending on risk, population data put the lower-risk end of the healthy distribution below about 80, and the lowest-risk tertile in a US sample sat near 60.

ApoB counts the particles that carry cholesterol into artery walls, one molecule per particle. It predicts heart disease better than LDL cholesterol and explains why two people with the same LDL can carry different risk. Laboratories usually print under 90 mg/dL as desirable; the evidence supports lower is better, by degree of risk and duration.

01 · The scale

Where the laboratory range and the evidence sit.

Lower is better with no floor found. Guidelines set goals of under 100, 80 or 65 mg/dL by risk; discordantly high ApoB raises risk even when LDL cholesterol looks fine; the healthy population's lower half sits below about 80.

0406580100130160

Common laboratory 'desirable' cutoff
0 to 90 mg/dL · Typical US laboratories
Very-high-risk goal
0 to 65 mg/dL · ESC/EAS 2019
High-risk goal
65 to 80 mg/dL · ESC/EAS 2019; CCS 2021
Moderate-risk goal; NLA and AACE goal under 90
80 to 100 mg/dL · ESC/EAS 2019; NLA 2015; AACE 2017
Risk-enhancing factor at 130 and above
130 and above mg/dL · AHA/ACC 2018

Laboratory range
Evidence supports
Guideline goal or unstudied
Higher risk in studies

Scale in mg/dL. Some laboratories report g/L; multiply by 100 for mg/dL. Bands show where studies found something, not a recommendation for any one person.

02 · What it is

What ApoB measures.

Every atherogenic lipoprotein (LDL, VLDL, IDL, remnants and lipoprotein(a)) carries one molecule of apolipoprotein B, so the ApoB concentration is a particle count. Cholesterol enters the artery wall only inside those particles, and the number trapped there, not the cholesterol each carries, drives atherosclerosis.¹Grade A

The causal chain is unusually well established. Genetic variants that lower LDL, trials that lower it by drug, and more than 200 prospective cohorts agree on a dose-dependent, log-linear relationship between lifetime exposure to these particles and cardiovascular disease, and the effect grows with the years of exposure.^2,3Grade A

When genetic variants that lower triglycerides and variants that lower LDL cholesterol were compared across 654,783 people, each 10 mg/dL lower ApoB carried the same 23 percent lower coronary risk whichever pathway produced it, and after accounting for ApoB, triglycerides and LDL cholesterol themselves no longer predicted anything. ApoB is the quantity that matters.^4,5Grade A

03 · The laboratory range

What a laboratory calls normal.

Under 90 mg/dL printed as desirable by most US laboratories; some flag only above 130.

Population data map LDL cholesterol to ApoB imperfectly. In 12,688 US adults the median ApoB was 49 mg/dL at an LDL of 55, 60 at an LDL of 70, 80 at an LDL of 100 and 140 at an LDL of 190, but at an LDL of 100 the central 95 percent of ApoB values spread from 66 to 99. Even metabolically healthy people were often discordant, which is why the authors call the guideline practice of measuring ApoB only when triglycerides are high too narrow.⁶Grade B

The 2018 American cholesterol guideline treats an ApoB of 130 mg/dL or above as a risk-enhancing factor and suggests measuring it when triglycerides are 200 or higher. That is a threshold for escalating treatment decisions, not a definition of health.⁷Grade A

04 · The evidence

What the studies support.

The European dyslipidaemia guideline sets ApoB goals of under 65 mg/dL for very-high-risk, under 80 for high-risk and under 100 for moderate-risk adults, and recommends ApoB for risk assessment, preferring it to LDL cholesterol when triglycerides are high, in diabetes, obesity, metabolic syndrome or very low LDL. The Canadian guideline likewise prefers ApoB or non-HDL cholesterol over LDL when triglycerides exceed 1.5 mmol/L (133 mg/dL). The National Lipid Association and the American endocrinology society set an ApoB goal under 90 for high risk and under 80 for very high risk.^8,9,10,11Grade A

Across 12 cohorts with 233,455 people and 22,950 events, ApoB was the strongest of the three lipid markers for cardiovascular events (relative risk per standard deviation 1.43), non-HDL cholesterol intermediate (1.34) and LDL cholesterol weakest (1.25). The Emerging Risk Factors Collaboration found the same in 302,430 people and showed that fasting is unnecessary for ApoB.^12,13Grade A

In the UK Biobank, among 389,529 people without heart disease, ApoB, non-HDL cholesterol and triglycerides each predicted heart attacks alone, but when modeled together only ApoB remained (27 percent higher risk per standard deviation). The type of particle and its cholesterol content added nothing once the particle count was known.¹⁴Grade B

In 13,015 statin-treated Danish adults, those with ApoB above the median but LDL cholesterol below it had 21 percent higher all-cause mortality and 49 percent more heart attacks than people with both low; the reverse discordance, high LDL with low ApoB, carried no excess. The number of particles, not the cholesterol number, carried the residual risk.¹⁵Grade B

Using genetic variants as a natural experiment in UK Biobank, higher ApoB shortened parental lifespan and raised the risks of heart disease and stroke; after accounting for LDL cholesterol it also raised type 2 diabetes risk. Mendelian randomization supports a causal, lifelong, dose-dependent effect.¹⁶Grade B

05 · What moves it

The levers with evidence behind them.

What is listed here has been tested. The size of each effect, and the size of the study, are in the sentence, so a small effect reads as a small effect.

Replacing saturated and trans fat with unsaturated fat
lowers it
A meta-analysis of 60 controlled feeding trials found ApoB falls when saturated fatty acids are replaced by cis-unsaturated fats; replacing fat with carbohydrate did not improve the total-to-HDL ratio and raised triglycerides. Trans fats were the most harmful per calorie.¹⁷Grade A
Viscous fiber such as psyllium
lowers it modestly
Across 28 randomized trials, a median of about 10 grams of psyllium a day lowered ApoB by 0.05 g/L (5 mg/dL) and LDL cholesterol by 13 mg/dL, with the ApoB estimate graded high quality.¹⁸Grade A
Exercise training
lowers it a little
Pooled trials of exercise training show a statistically significant but small reduction in ApoB, far smaller than diet change or medication; exercise earns its place on this page for the other things it does.¹⁹Grade B
Lipid-lowering medication
lowers it substantially
Medications that lower LDL cholesterol lower ApoB by a comparable fraction, and the guidelines' ApoB goals assume them for people at high risk. Whether and when to treat is a decision for a physician who knows the person's risk, not a page.⁸Grade A

06 · Reading it well

Caveats, and what belongs with a physician.

ApoB is measured directly and standardized internationally, which is one reason it tracks risk better than a calculated LDL cholesterol; the spread of ApoB at any LDL value is widest when LDL is estimated by the Friedewald equation.⁶Grade B

Lipoprotein(a) is an ApoB particle and is included in the count, but it carries extra risk of its own and is inherited; a high ApoB deserves a once-in-a-lifetime lipoprotein(a) measurement, which the Canadian guideline now recommends for everyone.⁹Grade A

The guideline goals are treatment targets for people already judged at risk, drawn from trials of drugs; they are not population definitions of health, and no trial has randomized healthy adults to ApoB targets.^8,7Grade A

See a physician

An ApoB of 130 mg/dL or higher, or an LDL cholesterol of 190 or higher, which can signal familial hypercholesterolemia.
A parent or sibling with a heart attack, stroke or stent before 55 (men) or 65 (women).
A high ApoB with diabetes, high blood pressure, kidney disease or a smoking history.
Chest pressure, breathlessness on exertion, or pain in the calves when walking, regardless of any lipid number.

This page is education, not individual medical advice, and reading it creates no physician-patient relationship.

07 · Open questions

What the literature does not settle.

No outcome trial has used ApoB as its primary target; every ApoB goal is translated from LDL-lowering trials and from where risk sat in cohorts.
The cumulative-exposure argument implies that lower ApoB from early adulthood matters most, but no trial has tested long-term lowering in healthy young adults.
The guidelines disagree on the numbers (65, 80, 90, 100) because they draw the risk categories differently, not because the biology differs.
ApoB is still not on most routine panels in the US, so population reference data are thinner than for LDL cholesterol.

08 · In practice

How Dr. Tagge reads it in his own practice.

I measure ApoB on nearly everyone, because it is the particle count that reaches the artery wall. I like to see it under 90, and lower, under 80, when there is family history, high lipoprotein(a), diabetes or high blood pressure. I read it as a lifetime exposure, so the age at which it is lowered matters as much as the number.

A practice judgment, labeled as one (Grade D): it is how one physician reads the number for the people he cares for, not a recommendation for you.

Questions

10 · Sources

19 sources, read in full.

Numbered in the order they appear. Each line says what this page relies on from the paper; the link opens the record at PubMed or the publisher.

1.
Sniderman AD, Thanassoulis G, Glavinovic T, et al.. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiology. 2019. PMID 31642874. DOI 10.1001/jamacardio.2019.3780.
Review · Cholesterol enters the artery wall only inside ApoB particles; particle number determines deposition.
2.
Ference BA, Ginsberg HN, Graham I, et al.. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal. 2017. PMID 28444290. DOI 10.1093/eurheartj/ehx144.
Consensus statement · Dose-dependent, log-linear, causal relationship between cumulative LDL exposure and cardiovascular disease across genetics, cohorts and trials.
3.
Ference BA, Braunwald E, Catapano AL. The LDL cumulative exposure hypothesis: evidence and practical applications. Nature Reviews Cardiology. 2024. PMID 38969749. DOI 10.1038/s41569-024-01039-5.
Review · Risk depends on both the magnitude and the duration of exposure to LDL particles.
4.
Ference BA, Kastelein JJP, Ray KK, et al.. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019. PMID 30694319. DOI 10.1001/jama.2018.20045.
Mendelian randomization · Each 10 mg/dL lower ApoB carried the same 23 percent lower coronary risk whichever gene produced it; triglycerides and LDL-C added nothing after ApoB.
5.
Richardson TG, Sanderson E, Palmer TM, et al.. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. PLoS Medicine. 2020. PMID 32203549. DOI 10.1371/journal.pmed.1003062.
Mendelian randomization · ApoB is the predominant lipid trait accounting for the causal relationship with coronary heart disease.
6.
Sayed A, Peterson ED, Virani SS, Sniderman AD, Navar AM. Individual variation in the distribution of apolipoprotein B levels across the spectrum of LDL-C or non-HDL-C levels. JAMA Cardiology. 2024. PMID 38865115. DOI 10.1001/jamacardio.2024.1310.
Cross-sectional study · Median ApoB 49, 60, 80 and 140 mg/dL at LDL-C 55, 70, 100 and 190; at LDL-C 100 the 95 percent range was 66 to 99.
7.
Grundy SM, Stone NJ, Bailey AL, et al.. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation. 2019. PMID 30586774. DOI 10.1161/CIR.0000000000000625.
Guideline · ApoB 130 mg/dL or above is a risk-enhancing factor; measure when triglycerides are 200 or higher.
8.
Mach F, Baigent C, Catapano AL, et al.. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2020. PMID 31504418. DOI 10.1093/eurheartj/ehz455.
Guideline · ApoB goals under 65, 80 and 100 mg/dL for very-high, high and moderate risk; ApoB preferred over LDL-C with high triglycerides, diabetes, obesity or very low LDL-C.
9.
Pearson GJ, Thanassoulis G, Anderson TJ, et al.. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Canadian Journal of Cardiology. 2021. PMID 33781847. DOI 10.1016/j.cjca.2021.03.016.
Guideline · ApoB or non-HDL-C preferred over LDL-C when triglycerides exceed 1.5 mmol/L; lipoprotein(a) once in a lifetime.
10.
Jacobson TA, Ito MK, Maki KC, et al.. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1, full report. Journal of Clinical Lipidology. 2015. PMID 25911072. DOI 10.1016/j.jacl.2015.02.003.
Guideline · ApoB goal under 90 mg/dL for moderate and high risk, under 80 for very high risk.
11.
Jellinger PS, Handelsman Y, Rosenblit PD, et al.. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocrine Practice. 2017. PMID 28437620. DOI 10.4158/EP171764.APPGL.
Guideline · ApoB goals under 90 (high risk), under 80 (very high risk) and under 70 (extreme risk) mg/dL.
12.
Sniderman AD, Williams K, Contois JH, et al.. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circulation: Cardiovascular Quality and Outcomes. 2011. PMID 21487090. DOI 10.1161/CIRCOUTCOMES.110.959247.
Systematic review and meta-analysis · ApoB the strongest lipid marker of cardiovascular events (RRR 1.43), LDL-C the weakest (1.25), across 233,455 people.
13.
Emerging Risk Factors Collaboration; Di Angelantonio E, Sarwar N, et al.. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009. PMID 19903920. DOI 10.1001/jama.2009.1619.
Systematic review and meta-analysis · Apolipoproteins predicted coronary disease at least as well as cholesterol fractions, with no need to fast.
14.
Marston NA, Giugliano RP, Melloni GEM, et al.. Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content. JAMA Cardiology. 2022. PMID 34773460. DOI 10.1001/jamacardio.2021.5083.
Prospective cohort · Only ApoB remained associated with myocardial infarction when modeled with non-HDL-C and triglycerides (HR 1.27 per SD).
15.
Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. Journal of the American College of Cardiology. 2021. PMID 33736827. DOI 10.1016/j.jacc.2021.01.027.
Prospective cohort · High ApoB with low LDL-C: HR 1.21 for mortality and 1.49 for myocardial infarction; high LDL-C with low ApoB carried no excess.
16.
Richardson TG, Wang Q, Sanderson E, et al.. Effects of apolipoprotein B on lifespan and risks of major diseases including type 2 diabetes: a mendelian randomisation analysis using outcomes in first-degree relatives. Lancet Healthy Longevity. 2021. PMID 34729547. DOI 10.1016/S2666-7568(21)00086-6.
Mendelian randomization · Genetically higher ApoB shortened lifespan and raised heart disease, stroke and, after adjusting for LDL-C, diabetes risk.
17.
Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. American Journal of Clinical Nutrition. 2003. PMID 12716665. DOI 10.1093/ajcn/77.5.1146.
Systematic review and meta-analysis · Replacing saturated with cis-unsaturated fat lowers ApoB and the total-to-HDL ratio; carbohydrate replacement does not.
18.
Jovanovski E, Yashpal S, Komishon A, et al.. Effect of psyllium (Plantago ovata) fiber on LDL cholesterol and alternative lipid targets, non-HDL cholesterol and apolipoprotein B: a systematic review and meta-analysis of randomized controlled trials. American Journal of Clinical Nutrition. 2018. PMID 30239559. DOI 10.1093/ajcn/nqy115.
Systematic review and meta-analysis · About 10 g/day psyllium lowered ApoB by 0.05 g/L and LDL-C by 0.33 mmol/L across 28 trials.
19.
Downes D, Goodman S, van der Touw T, et al.. Effect of exercise training on apolipoproteins: meta-analysis and trial sequence analysis. International Journal of Sports Medicine. 2025. PMID 40203891. DOI 10.1055/a-2580-0722.
Systematic review and meta-analysis · Exercise training produced a small, statistically significant reduction in ApoB.

Keep reading.

Reading a number well is the start of the work, not the end of it. If you would like a physician to read yours over time, Explore working with Dr. Tagge.